Literature DB >> 8848524

CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study.

C Nordin1, B Almé, U Bondesson.   

Abstract

With the aim of exploring putative correlations between serum and CSF levels of clozapine and its demethyl metabolite, lumbar puncture was performed on four male and five female schizophrenic patients during long-term treatment with clozapine. Three consecutive 6-ml fractions were collected after at least 8 h of bedrest and fasting. On comparing serum and CSF levels, a correlation was found for norclozapine in the third (13-18 ml) CSF fraction. Norclozapine in the first (0-6 ml) CSF correlated significantly with height. The CSF/serum ratio of clozapine in the first fraction was correlated significantly with body weight. No correlations were found between serum levels of clozapine and norclozapine, or between the serum and CSF levels of clozapine. The study suffers from a small number of patients (for ethical reasons), but the present results might be explicable if the first (0-6 ml) CSF fraction represents a cul-du-sac of the CSF, mirroring the previous day's drug levels. The second fraction, then, will represent the CSF level in the steady state during the night.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8848524     DOI: 10.1007/bf02246083

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

Review 1.  Clozapine--pharmacokinetic investigations and biochemical effects in man.

Authors:  M Ackenheil
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Clozapine concentrations and clinical response in schizophrenic patients.

Authors:  J A Owen; N J Delva; J S Lawson
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

Review 3.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

4.  [Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl)].

Authors:  M Ackenheil; H Bräu; A Burkhart; A Franke; W Pacha
Journal:  Arzneimittelforschung       Date:  1976

5.  Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age.

Authors:  C Haring; U Meise; C Humpel; A Saria; W W Fleischhacker; H Hinterhuber
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients.

Authors:  P J Perry; D D Miller; S V Arndt; R J Cadoret
Journal:  Am J Psychiatry       Date:  1991-02       Impact factor: 18.112

7.  Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

Authors:  M H Kronig; R A Munne; S Szymanski; A Z Safferman; S Pollack; T Cooper; J M Kane; J A Lieberman
Journal:  Am J Psychiatry       Date:  1995-02       Impact factor: 18.112

8.  Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking.

Authors:  M Hasegawa; R Gutierrez-Esteinou; L Way; H Y Meltzer
Journal:  J Clin Psychopharmacol       Date:  1993-12       Impact factor: 3.153

9.  Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study.

Authors:  O V Olesen; K Thomsen; P N Jensen; C H Wulff; N A Rasmussen; C Refshammer; J Sørensen; M Bysted; J Christensen; R Rosenberg
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

10.  CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite.

Authors:  C Nordin; L Bertilsson; B Siwers
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

View more
  7 in total

1.  Effect fingerprints of antipsychotic drugs on neural networks in vitro.

Authors:  Philipp Görtz; Uwe Henning; Stephan Theiss; Christian Lange-Asschenfeldt
Journal:  J Neural Transm (Vienna)       Date:  2019-07-18       Impact factor: 3.575

2.  The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets.

Authors:  N Sasaki; M Iwase; Y Uchizono; U Nakamura; H Imoto; S Abe; M Iida
Journal:  Diabetologia       Date:  2006-10-27       Impact factor: 10.122

3.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Authors:  D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

Review 4.  What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia.

Authors:  Peter Schulte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance.

Authors:  G Schaber; I Stevens; H J Gaertner; K Dietz; U Breyer-Pfaff
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

6.  Clozapine protects adult neural stem cells from ketamine-induced cell death in correlation with decreased apoptosis and autophagy.

Authors:  Mathias Lundberg; Sophie Curbo; Hannes Bohman; Ingrid Agartz; Sven-Ove Ögren; Cesare Patrone; Shiva Mansouri
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

7.  Mitochondrial DNA copy number is associated with psychosis severity and anti-psychotic treatment.

Authors:  Parvin Kumar; Paschalis Efstathopoulos; Vincent Millischer; Eric Olsson; Ya Bin Wei; Oliver Brüstle; Martin Schalling; J Carlos Villaescusa; Urban Ösby; Catharina Lavebratt
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.